Renal Cell Cancer Registry in Latin American Clinical-phatological Characterization and Outcomes of Renal Cell Carcinoma in Latin America

Latin American Cooperative Oncology Group16 sites in 1 country211 target enrollmentSeptember 1, 2022

ConditionsKidney Neoplasms

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Kidney Neoplasms
Sponsor: Latin American Cooperative Oncology Group
Enrollment: 211
Locations: 16
Primary Endpoint: Build a real-life renal cell cancer database in Brazil and Latin America
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Observational study, retrospective and prospective, of an analytical nature. Data will be collected from medical records and/or through contact with physicians and institutions (secondary data collection). Patients included retrospectively or prospectively will be followed during the data collection period for the evaluation of treatments and survival. No intervention is planned in this protocol.

Registry

clinicaltrials.gov

Start Date

September 1, 2022

End Date

July 11, 2024

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Latin American Cooperative Oncology Group

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients ≥ 18 years of age;
•Proven histology of renal cell carcinoma (any subtype);
•Pathological diagnosis of renal cell carcinoma in January 2015 or later and new cases diagnosed during the period of recruitment of each center;
•Have the medical record available and suitable for collecting data on patient characteristics, treatment and outcome.

Exclusion Criteria

•Synchronous or other primary tumor within the last 3 years (except thyroid cancer or non melanoma skin).

Outcomes

Primary Outcomes

Build a real-life renal cell cancer database in Brazil and Latin America

Time Frame: 2022

Secondary Outcomes

Progression-free survival in each therapeutic line(2022)
Causes of delay or discontinuation of each treatment checklist(2022)
Time between diagnosis and start of treatment.(2022)
Overall survival(2022)
Clinicopathological characteristics of patients with renal cell cancer checklist(2022)
Sociodemographic characteristics checklist(2022)
Characteristics of systemic treatment checklist(2022)